Initial Data from Ph 3 Trial Demonstrating 75% CRR at 3 Months with nadofaragene firadenove) in BCG-unresponsive Japanese NMIBC Patients Announced April 30, 2025
Ivonescimab + Chemo combo yields Statistically Significant PFS vs. Tislelizumab + Chemo in Chinese Patients with 1L Squamous NSCLC in HARMONi-6 Study April 30, 2025
Sasanlimab Combination Significantly Improves EFS in BCG-Naïve, High-Risk NMIBC, but misses OS endpoint April 30, 2025
Positive Interim Results Demonstrating Durable Responses in Ongoing Ph 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC Announced April 30, 2025
New long-term PFS data projections reinforce SC DARZALEX quadruplet therapy as a foundational SoC for patients with newly diagnosed multiple myeloma April 30, 2025
TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC April 30, 2025
TAR-200 monotherapy demonstrates highest CRR reported to date with sustained clinical benefits in patients with certain types of bladder cancer April 30, 2025
Trodelvy + Keytruda Demonstrate Statistically Significant PFS Improvement in Patients With 1L PD-L1+ Metastatic TNBC April 30, 2025
OLYMPUS Long-Term Follow-Up shows Nearly 4-Year DoR in Patients with LG-UT Urothelial Cancer Who Achieved a Complete Response to prior JELMYTO Treatment April 30, 2025
Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec announced April 30, 2025
FAILED TRIAL: ASPEN-03 and ASPEN-04 Ph 2 Trials of Evorpacept + Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints April 30, 2025
Interim OS Analysis Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab vs Keytruda in PD-L1+ve Advanced NSCLC from HARMONi-2 Study April 30, 2025
TAR-200 monotherapy shows highest complete response with sustained benefits in 12-month data from Ph 2b SunRISe-1 study (Cohort 2) in NMIBC patients April 22, 2025
Enhertu + pertuzumab in DESTINY-Breast09 Ph 3 trial demonstrated PFS improvement in vs THP as a 1L treatment for patients with HER2-positive metastatic breast cancer April 22, 2025
Preliminary results from Ph 2 IPAX-Linz study of TLX101 (131I-iodofalan1) in recurrent high-grade glioma announced April 22, 2025
Ph 2 study of Bria-IMT + CPI outperforms ADC drugs in HR+ metastatic breast cancer (MBC) patients April 22, 2025
Trodelvy + Keytruda Demonstrated PFS Improvement in Patients With Previously Untreated PD-L1+ Metastatic TNBC April 22, 2025
Ph 3 DeLLphi-304 trial of IMDELLTRA (tarlatamab-dlle) in SCLC patients met primary endpoint at a planned interim analysis April 16, 2025
SON-1010 + Atezolizumab combo Demonstrates a Strong Safety Profile in Platinum-Resistant Ovarian Cancer patients April 15, 2025
Tovecimig (CTX-009) Meets Primary Endpoint in Ph 2/3 Study in Patients with Biliary Tract Cancer April 8, 2025
